American Journal of Clinical Dermatology

, Volume 17, Issue 6, pp 643–652 | Cite as

Drug-Induced Tactile Hallucinations Beyond Recreational Drugs

Review Article

Abstract

In monosymptomatic hypochondriacal psychosis (MHP), such as delusional infestation (DI), the patient has a fixed, false, encapsulated belief associated with tactile hallucinations (TH), most commonly formication, which is defined as cutaneous sensations of crawling, stinging, biting, etc., without evidence of infestation. Drug-induced TH should be considered in patients with suspected MHP. Although recreational drugs such as cocaine, amphetamines, and narcotics are well known to induce TH, many busy practicing dermatologists may not be familiar with other types of medications that can induce TH. A literature search for peer-reviewed articles was conducted in the PubMed, PsychInfo, Cochrane, and Embase databases. For each article, the medication(s) that induced TH was identified in a systematic way. The most commonly reported group of medications to induce TH was anti-Parkisonian agents, followed by antidepressants, prescription stimulants, antihypertensives (propranolol), and antiepileptics. In many cases, other types of hallucinations, such as visual and auditory, were present. Patients also commonly presented with psychiatric comorbidities. Although the conclusions that can be derived from this literature review are limited, it appears that certain medications that alter neurotransmitters, especially dopamine and, less convincingly, norepinephrine and serotonin, can be associated with TH. Drug-induced TH should also be considered in patients presenting with multiple types of hallucinations and patients with existing psychiatric comorbidity. Drug-induced TH, especially with an underlying psychiatric diagnosis that is separate from MHP, may be a more manageable disease entity compared with bona fide MHP.

References

  1. 1.
    Vulink NC. Delusional infestation: state of the art. Acta Derm Venereol. 2016;96:58–63.PubMedGoogle Scholar
  2. 2.
    Freudenmann RW, Lepping P. Delusional infestation. Clin Microbiol Rev. 2009;22:690–732.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.CrossRefGoogle Scholar
  4. 4.
    Koo J. Psychodermatology: a practical manual for clinicians. Curr Probl Dermatol. 1995;7:199–234.CrossRefGoogle Scholar
  5. 5.
    Wong JW, Koo J. Delusions of parasitosis. Indian J Dermatol. 2013;58(1):49–52.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wykoff RF. Delusions of parasitosis: a review. Rev Infect Dis. 1987;9(3):433–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in Parkinsonian patients. Neurology. 1998;51:811–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psych. 1978;135:669–75.CrossRefGoogle Scholar
  9. 9.
    Kataoka H, Sawa N, Sugie K, Ueno S. Dopamine agonists trigger tactile hallucinations in patients with Pakinson’s Disease? J Neurol Sci. 2014;347:361–3.CrossRefPubMedGoogle Scholar
  10. 10.
    Flann S, Shotbolt J, Kessel B, et al. Three cases of delusional parasitosis caused by dopamine agonists. Clin Exp Dermatol. 2010;35(7):740–2.CrossRefPubMedGoogle Scholar
  11. 11.
    Swick B, Walling H. Drug-induced delusions of parasitosis during treatment of Parkinson’s disease. J Am Acad Dermatol. 2005;53:1086–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Fénelon G, Thobois S, Bonnet AM, Broussolle E, Tison F. Tactile hallucinations in Parkinson’s disease. J Neurol. 2002;249:1699–703.CrossRefPubMedGoogle Scholar
  13. 13.
    Jiménez-Jiménez FJ, Ortí-Pareja M, Gasalla T, Tallón-Barranco A, Cabrera-Valdivia F, Fernández-Lliria A. Cenesthetic hallucinations in a patient with Parkinson’s disease. J Neurol Neurosur Psychiatry. 1997;63:120.CrossRefGoogle Scholar
  14. 14.
    Wilcox J. Psychoactive properties of amantadine. J Psychoactive Drugs. 1985;17:51–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Shepherd G, Velez LI, Keyes DC. Intentional bupropion overdoses. J Emerg Med. 2004;27:147–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Arora GS, Arora HK, Sidhu J, Najjar F. Tactile hallucinations with fluoxetine and methylphenidate. J Child Adolesc Psychopharmacol. 2014;6:360–1.CrossRefGoogle Scholar
  17. 17.
    Coskun M, Zoroglu S. Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination. J Clin Psychopharmacol. 2008;28:723–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Charuvastra A, Yaeger D. Tactile hallucinations associated with therapeutic doses of bupropion in 2 patients. J Clin Psychiatry. 2006;67(11):1820–1.CrossRefPubMedGoogle Scholar
  19. 19.
    Liskin B, Roose SP, Walsh BT, Jackson WK. Acute psychosis following phenelzine discontinuation. J Clin Psychopharm. 1985;5(1):46–7.CrossRefGoogle Scholar
  20. 20.
    Peabody CA. Trazodone withdrawal and formication. J Clin Psychiatry. 1987;48(9):385.PubMedGoogle Scholar
  21. 21.
    Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA. Anticholinergic psychosis in a patient receiving usual doses of haloperidol, desipramine, and benztropine. Clin Pharm. 1983;2(2):174–8.PubMedGoogle Scholar
  22. 22.
    Liebowitz MR, Nuetzel EJ, Bowser AE, Klein DF. Phenelzine and delusions of parasitosis: a case report. Am J Psychiatry. 1978;135:1422–33.CrossRefGoogle Scholar
  23. 23.
    Stanciu CN, Penders TM, Oxentine HN. Delusional infestation following misuse of prescription stimulants. Psychosomatics. 2015;56(2):210–2.CrossRefPubMedGoogle Scholar
  24. 24.
    Buscarino M, Saal J, Young JL. Delusional parasitosis in a female treated with mixed amphetamine salts: a case report and literature review. Case Rep Psychiatry. 2012;2012:624235.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Rashid J, Mitelman S. Methylphenidate and somatic hallucinations. J Am Acad Child Psychiatry. 2007;46(8):945–6.CrossRefGoogle Scholar
  26. 26.
    Young JG. Methylphenidate-induced hallucinosis: case histories and possible mechanisms of action. J Dev Behav Pediatr. 1981;2:35–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Horn JR, Rylander ML, Hicks HM. Propranolol-induced hallucinosis. Clin Pharm. 1982;1(5):464–8.PubMedGoogle Scholar
  28. 28.
    Kurland ML. Organic brain syndrome with propranolol. N Engl J Med. 1979;300(7):366.PubMedGoogle Scholar
  29. 29.
    Hinshelwood RD. Hallucinations and propranolol. Br Med J. 1969;2:445.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Moreira CA, Soares AR, Maia G. Psychiatric antiepileptics side effects: a case report. Eur Psychiatry. 2016;33(Suppl):S348.Google Scholar
  31. 31.
    Oh HK, Tebrewal P, Dhillon R. Lamotrigine-induced tactile hallucination. J Clin Psychiatry. 2014;75(11):e1330.CrossRefPubMedGoogle Scholar
  32. 32.
    Shrestha PV, Syed A, Marwaha R. Lacosamide-induced tactile hallucinations in a patient with complex partial seizures. J Neuropsychiatry Clin Neurosci. 2014;26(3):E8–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Mukonzo JK, Okwera A, Nakasujja N, et al. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis. 2013;4(13):261.CrossRefGoogle Scholar
  34. 34.
    Brandt LJ. Formication and azathioprine therapy. Ann Intern Med. 1977;87(4):458.CrossRefPubMedGoogle Scholar
  35. 35.
    Siemianowski LA, Rosenheck JP, Whitman CB. Nalbuphine-induced psychosis treated with naloxone. Am J Health Syst Pharm. 2014;71:717–21.CrossRefPubMedGoogle Scholar
  36. 36.
    Selvaraj V, Skaf M, Sharma A, Farooq U, Frederick P. Eszopiclone-induced psychosis. Innov Clin Neurosci. 2012;9(10):11.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Patel V, Koo JY. Delusions of parasitosis: suggested dialogue between dermatologist and patient. J Dermatolog Treat. 2015;26(5):456–60.CrossRefPubMedGoogle Scholar
  38. 38.
    Elpern DJ. Cocaine abuse and delusions of parasitosis. Cutis. 1988;42(4):273–4.PubMedGoogle Scholar
  39. 39.
    Bell DS. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry. 1973;29:35–40.CrossRefPubMedGoogle Scholar
  40. 40.
    Botschev C, Müller N. Opiate receptor antagonists for delusions of parasitosis. Biol Psychiatry. 1991;30(5):530–1.CrossRefPubMedGoogle Scholar
  41. 41.
    Vles J, Feron F, Hendriksen J, Jolles J, Van Kroonenburgh M, Weber W. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit. Neuropediatrics. 2003;34:77–80.CrossRefPubMedGoogle Scholar
  42. 42.
    Huber M, Kirchler E, Karner M, et al. Delusional parasitosis and the dopamine transporter. A new insight of etiology? Med Hypotheses. 2007;68:1351–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Gershon ES, Goldstein RE, Moss AJ, et al. Psychosis with ordinary doses of propranolol. Ann Intern Med. 1979;90:938–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Arensberg D, Wenger NK. Psychosis: a probable result of propranolol therapy. Int J Addict. 1979;14(6):785–7.CrossRefPubMedGoogle Scholar
  45. 45.
    McGahan DJ, Wojslaw A, Prasad V, Blankenship S. Propranolol-induced psychosis. Ann Pharmacother. 1984;18(7–8):601–3.CrossRefGoogle Scholar
  46. 46.
    Huffman JC, Stern TA. Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin Neurosci. 2007;9(1):29–45.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984;35:2505–11.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations